New drug G1090N tested in healthy volunteers for first time
NCT ID NCT07110441
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested the safety and how the body handles a new drug called G1090N in 52 healthy adults. Participants received single or multiple doses up to 1200 mg. The goal was to measure drug levels in blood and urine, and check for side effects. This is a first step before testing the drug in people with acute-on-chronic liver failure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- G1090N
- What this could lead to
- If successful, this could support further testing of G1090N as a potential treatment for acute-on-chronic liver failure.
- What could go wrong
- This is a very early Phase 1 study in healthy volunteers, not patients. It only measures safety and drug processing, not whether the drug works for liver failure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE-ON-CHRONIC LIVER FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anaheim Clinical Trials, LLC
Anaheim, California, 92801, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental injection aims to combat Life-Threatening liver failure
- Blood transfusion strategy could be refined for liver patients
- Could stem cells offer a lifeline for sudden liver failure?
- New device aims to filter toxins in liver crisis
- New device aims to filter toxic iron from blood in liver failure patients
- New blood test could save lives in liver failure bleeding emergencies